首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

2126441

人工智慧驅動的分子診斷市場－策略分析與預測（2026-2035）

AI-Powered Molecular Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

人工智慧驅動的分子診斷市場預計將以 11.4% 的複合年成長率成長，從 2026 年的 15.8 億美元成長到 2035 年的 41.6 億美元。

全球人工智慧驅動的分子診斷市場正經歷快速轉型，其驅動力來自基因組檢測數量的不斷成長和分子數據日益複雜的趨勢。人工智慧驅動的分子診斷將計算智慧與分子生物學相結合，旨在改善疾病檢測、基因組分析、生物標記發現、治療方案選擇以及患者長期監測。該市場透過快速解讀定序、轉錄組學、蛋白質組學和分子病理學平台產生的高維度生物數據，為精準醫療提供支援。隨著次世代定序在癌症和遺傳疾病檢測中應用日益廣泛，對人工智慧驅動的突變解讀的需求也隨之成長，市場需求不斷攀升。人工基因組分析已無法有效處理日益成長的定序資料量，臨床檢查室需要標準化的解讀流程，以在維持分析有效性的同時降低報告差異。人工智慧平台支援自動化品管、致病性預測和實證臨床報告。醫療保健系統在個人化醫療決策中越來越依賴分子診斷，這使得在不影響分析準確性的前提下縮短報告時間的壓力日益增大。政府機構和監管機構持續加強基因組醫學發展，增加對數位醫療基礎設施和標準化臨床資料集的投資。檢驗的運算模型提高了醫療機構間的一致性，這些措施正在加速人工智慧診斷平台的廣泛應用。

市場促進因素

精準腫瘤學的日益普及，擴大了對人工智慧驅動的基因組分析的需求。

在精準腫瘤學中，準確的分子特徵分析對於識別能夠從標靶治療和免疫治療中獲益的患者至關重要。隨著全基因組分析的日益普及，定序量不斷成長，人工解讀也變得越來越耗費資源。臨床檢查室正在採用人工智慧驅動的突變解讀平台，這些平台能夠優先識別具有臨床意義的突變並自動進行證據審查，使專家能夠專注於複雜的臨床決策。這種轉變提高了診斷效率，同時也提升了整個腫瘤檢測流程的一致性。

隨著定序需求的增加，我們對人工智慧驅動的生物資訊學的依賴也越來越大。

次世代定序會產生大量的基因組資料集，在進行臨床報告之前需要進行計算分析。隨著其在腫瘤學、感染疾病監測和罕見疾病診斷等領域的日益普及，檢查室的工作量已經超過了傳統分析方法的處理能力。基於人工智慧的生物資訊平台能夠自動完成突變過濾、註釋和分類，同時提高檢查室間的可重複性。因此，分子診斷服務提供者正日益注重平台的差異化，不再僅僅依靠定序硬體，而是透過整合分析能力來實現差異化。

感染疾病監測的擴大正在加速人工智慧與分子診斷的融合。

分子診斷技術能夠快速檢測病原體、進行基因組監測和抗生素抗藥性監測。新興感染疾病的出現需要持續的基因組監測，促使公共衛生機構擴大病原體定序計畫。人工智慧演算法透過識別數千個病原體序列之間的基因組關聯，提高了疫情檢測的準確性，並加快了流行病學解讀。這些能力推動了對結合檢查室自動化和計算分析的智慧分子診斷平台的需求。

製藥領域的生物標記開發正在推動人工智慧在分子檢測整體的應用。

由於標靶治療需要精準的患者分層，製藥公司正日益將分子生物標記納入其臨床開發流程。基因組學、轉錄組學和蛋白質組學中生物標記的日益複雜化，為傳統的統計方法帶來了分析挑戰。人工智慧平台能夠整合多模態生物資料集，識別預測性生物標記物，並最佳化伴隨診斷的開發。這種能力不僅加強了製藥公司與分子診斷服務提供者之間的合作，同時也推動了對人工智慧驅動的分析軟體的長期需求。

市場限制因素

人工智慧演算法在臨床應用方面仍面臨許多限制，因為在醫療機構將其納入常規分子診斷之前，需要進行廣泛的多中心檢驗。自適應機器學習軟體的法規核准仍然很複雜，因為它需要持續的效能監測和生命週期文件記錄，以證明其臨床安全性和有效性。資料隱私要求限制了機構間基因組資料的共用的訪問，而這些資料集對於提升人工智慧模型的性能和泛化能力至關重要。

市場定義和範圍
行業概覽
產業變化
主要市場趨勢
實際成果值市場規模分析
市場預測
分子診斷工作流程與人工智慧整合
分子診斷平台中人工智慧的應用現狀
測試數量分析
已安裝單元數量的分析
檢查室實施狀況分析
臨床效用及對醫療保健的影響

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

分子診斷領域新興的人工智慧技術
產品創新分析
臨床試驗分析
管道分析
人工智慧演算法的發展趨勢
數位病理學和多體學學整合
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求
人工智慧軟體檢驗和效能標準
資料隱私和網路安全要求

第8章：人工智慧驅動的分子診斷市場：展望分析

分析：按技術平台
分析：透過分子檢測方法
分析：透過人工智慧功能
分析：透過臨床應用
分析：依檢體類型
分析：按最終用戶

第9章：人工智慧驅動的分子診斷市場：細分市場分析

透過技術
- 聚合酵素鏈鎖反應（PCR）
- 次世代定序（NGS）
- 恒溫核酸增幅技術（INAAT）
- DNA微陣列
- 其他
按組件
- 軟體
- 硬體
- 服務
透過使用
- 感染疾病診斷
- 瘤
- 遺傳疾病和罕見疾病檢測
- 產前和生殖健康篩檢
- 心血管疾病的診斷
- 神經病變
- 其他
依檢體類型
- 血
- 組織
- 唾液
- 尿
- 其他
最終用戶
- 醫院
- 臨床檢查室
- 製藥和生物技術公司
- 其他

第10章：人工智慧驅動的分子診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：人工智慧驅動的分子診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
瑞士
中國
日本
印度
韓國
澳洲
巴西

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Illumina, Inc.
QIAGEN NV
Guardant Health
Tempus AI
Abbott Laboratories
Siemens AG
Agilent Technologies
Koninklijke Philips NV

第14章：人工智慧驅動的分子診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009159

The AI-Powered Molecular Diagnostics Market is forecast to grow at a CAGR of 11.4%, reaching USD 4.16 billion in 2035 from USD 1.58 billion in 2026.

The global AI-powered molecular diagnostics market is undergoing rapid transformation, driven by the convergence of rising genomic testing volumes and the increasing complexity of molecular data. AI-powered molecular diagnostics combines computational intelligence with molecular biology to improve disease detection, genomic analysis, biomarker discovery, treatment selection, and longitudinal patient monitoring. The market supports precision medicine by enabling rapid interpretation of high-dimensional biological data generated from sequencing, transcriptomics, proteomics, and molecular pathology platforms. Demand is increasing because the expanding use of next-generation sequencing across oncology and inherited disease testing is creating a need for AI-based variant interpretation. Manual genomic analysis cannot efficiently manage growing sequencing volumes, and clinical laboratories require standardized interpretation pipelines that reduce reporting variability while maintaining analytical validity. AI platforms are supporting automated quality control, pathogenicity prediction, and evidence-based clinical reporting. Healthcare systems increasingly depend on molecular diagnostics for individualized treatment decisions, creating pressure to shorten reporting timelines without compromising analytical accuracy. Government agencies and regulatory authorities continue strengthening genomic medicine initiatives, increasing investment in digital health infrastructure and standardized clinical datasets. These initiatives encourage broader adoption of AI-enabled diagnostic platforms because validated computational models improve consistency across healthcare institutions.

Market Drivers

Increasing Adoption of Precision Oncology Is Expanding Demand for AI-Based Genomic Interpretation

Precision oncology depends on accurate molecular characterization to identify patients who benefit from targeted therapies and immunotherapies. Growing adoption of comprehensive genomic profiling is increasing sequencing output, making manual interpretation increasingly resource-intensive. Clinical laboratories are implementing AI-driven variant interpretation platforms that prioritize clinically significant mutations and automate evidence review, allowing specialists to focus on complex clinical decisions. This shift strengthens diagnostic efficiency while improving consistency across oncology testing workflows.

Growing Sequencing Volumes Are Increasing Dependence on AI-Enabled Bioinformatics

Next-generation sequencing produces extensive genomic datasets that require computational interpretation before clinical reporting. Expanding adoption across oncology, infectious disease surveillance, and rare disease diagnosis is increasing laboratory workloads beyond the capacity of conventional analytical methods. AI-based bioinformatics platforms automate variant filtering, annotation, and classification while improving reproducibility across laboratories. Molecular diagnostic providers therefore increasingly differentiate their platforms through integrated analytics rather than sequencing hardware alone.

Expansion of Infectious Disease Surveillance Is Accelerating AI Integration into Molecular Diagnostics

Molecular diagnostics enables rapid pathogen detection, genomic surveillance, and antimicrobial resistance monitoring. Public health agencies are expanding pathogen sequencing programs because emerging infectious diseases require continuous genomic monitoring. AI algorithms are improving outbreak detection by identifying genomic relationships across thousands of pathogen sequences while supporting faster epidemiological interpretation. These capabilities increase demand for intelligent molecular diagnostic platforms that combine laboratory automation with computational analytics.

Pharmaceutical Biomarker Development Is Strengthening AI Adoption Across Molecular Testing

Drug developers increasingly incorporate molecular biomarkers into clinical development because targeted therapeutics require accurate patient stratification. Biomarker complexity continues increasing across genomics, transcriptomics, and proteomics, creating analytical challenges for conventional statistical methods. AI platforms are integrating multimodal biological datasets to identify predictive biomarkers and optimize companion diagnostic development. This capability strengthens collaboration between pharmaceutical companies and molecular diagnostics providers while expanding long-term demand for AI-enabled analytical software.

Market Restraints

Clinical adoption remains constrained because AI algorithms require extensive multicenter validation before healthcare providers incorporate them into routine molecular diagnostics. Regulatory approval timelines remain complex since adaptive machine learning software requires continuous performance monitoring and lifecycle documentation to demonstrate clinical safety and effectiveness. Data privacy requirements limit cross-institutional genomic data sharing, reducing access to diverse training datasets needed to improve AI model performance and generalizability.

Technology and Segment Insights

By Component

Software represents the strategic foundation of the market because computational interpretation transforms raw molecular data into clinically actionable information. Sequencing platforms generate increasingly complex genomic datasets, increasing dependence on AI-enabled bioinformatics for variant annotation, pathogenicity prediction, and automated reporting. Healthcare organizations are investing in interoperable software platforms that integrate laboratory information systems, electronic health records, and clinical knowledge databases. This transition shifts competitive differentiation from analytical hardware toward intelligent software ecosystems that improve diagnostic efficiency while supporting regulatory compliance.

By Application

Oncology constitutes the largest application segment because targeted therapies require accurate molecular characterization before treatment initiation. Comprehensive genomic profiling continues expanding across solid tumors and hematological malignancies, increasing analytical complexity for clinical laboratories. AI platforms support automated interpretation of genomic variants while integrating biomarker evidence from continuously evolving scientific literature. Infectious disease diagnostics, genetic and rare disease testing, prenatal and reproductive health testing, cardiovascular disease diagnostics, and neurological disorders represent additional significant application areas.

By Sample Type

Blood remains the leading sample type because minimally invasive testing supports broad clinical adoption across oncology, infectious disease diagnostics, prenatal screening, and inherited disorder assessment. Liquid biopsy technologies are increasing demand for highly sensitive computational algorithms capable of identifying low-frequency molecular alterations from circulating biomarkers. AI-assisted signal processing improves analytical accuracy by distinguishing clinically relevant findings from background biological variation. Tissue, saliva, urine, and other sample types represent additional segments.

By End User

Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, and Other End Users represent the primary markets. Clinical laboratories are the largest adopters, integrating AI software with sequencing workflows to reduce reporting time while improving analytical consistency. Hospitals are expanding in-house molecular testing capabilities. Pharmaceutical companies utilize AI-powered diagnostics for biomarker discovery and companion diagnostic development.

Competitive and Strategic Outlook

The competitive landscape features major molecular diagnostics and life science companies. F. Hoffmann-La Roche Ltd. remains strategically distinct because it combines one of the world's largest molecular diagnostics portfolios with advanced pharmaceutical capabilities. Thermo Fisher Scientific Inc. differentiates itself through its broad life sciences ecosystem combining sequencing technologies, molecular diagnostics, and cloud-based bioinformatics. Illumina, Inc. maintains strategic leadership through its global dominance in next-generation sequencing technologies and investment in genomic informatics. QIAGEN N.V. distinguishes itself through its balanced portfolio of molecular testing technologies and bioinformatics software. Guardant Health has established a strong strategic position by specializing in liquid biopsy technologies for oncology. Tempus AI differentiates itself through a data-centric business model integrating molecular diagnostics, AI, and real-world evidence.
Strategic developments include increasing integration of multi-omics data, expansion of liquid biopsy applications, and growth of clinical decision support platforms. Companies are forming partnerships to strengthen algorithm development, clinical validation, and regulatory submissions. Technology expansions focus on AI-enabled variant interpretation, workflow automation, and cloud-based analytics. Companies that successfully integrate software intelligence, explainability, and data integration within scalable precision medicine platforms are expected to lead the market.

Conclusion

The AI-powered molecular diagnostics market is poised for significant growth, driven by the adoption of precision oncology, rising sequencing volumes, and AI integration. The evolution from laboratory-centered testing toward continuously learning clinical decision-support ecosystems is reshaping molecular diagnostics. Companies that successfully deliver clinically validated, scalable, and integrated AI-powered diagnostic solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding genomic medicine infrastructure will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1. Market Snapshot
1.2. Key Findings
1.3. Analyst Insights
1.4. Strategic Recommendations

2. Research Methodology

2.1. Research Design
2.2. Data Collection Methodology
2.3. Market Size Estimation
2.4. Forecasting Model
2.5. Assumptions & Limitations

3. AI-Powered Molecular Diagnostics Market Overview, Size & Forecast

3.1. Market Definition & Scope
3.2. Industry Overview
3.3. Industry Evolution
3.4. Key Market Trends
3.5. Historical Market Size Analysis (2021-2025)
3.6. Market Forecast (2026-2035)
3.7. Molecular Diagnostics Workflow and AI Integration
3.8. AI Adoption Across Molecular Diagnostic Platforms
3.9. Testing Volume Analysis
3.10. Installed Base Analysis
3.11. Laboratory Adoption Analysis
3.12. Clinical Utility and Healthcare Impact

4. Market Dynamics

4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Market Challenges

5. Industry Landscape

5.1. Industry Value Chain Analysis
5.2. Pricing Analysis
5.3. Reimbursement Landscape

6. Innovation Landscape

6.1. Emerging AI Technologies in Molecular Diagnostics
6.2. Product Innovation Analysis
6.3. Clinical Trial Analysis
6.4. Pipeline Analysis
6.5. AI Algorithm Development Trends
6.6. Digital Pathology and Multi-Omics Integration
6.7. Technology Roadmap

7. Regulatory Landscape

7.1. Regulatory Framework
7.2. Approval Pathways
7.3. Compliance Requirements
7.4. AI Software Validation and Performance Standards
7.5. Data Privacy and Cybersecurity Requirements

8. AI-Powered Molecular Diagnostics Market Landscape Analysis

8.1. Analysis by Technology Platform
8.2. Analysis by Molecular Testing Methodology
8.3. Analysis by AI Functionality
8.4. Analysis by Clinical Application
8.5. Analysis by Sample Type
8.6. Analysis by End User

9. AI-Powered Molecular Diagnostics Market Segment Analysis (2021-2035)

9.1. By Technology
- 9.1.1. Polymerase Chain Reaction (PCR)
- 9.1.2. Next-Generation Sequencing (NGS)
- 9.1.3. Isothermal Nucleic Acid Amplification Technologies (INAAT)
- 9.1.4. DNA Microarrays
- 9.1.5. Others
9.2. By Component
- 9.2.1. Software
- 9.2.2. Hardware
- 9.2.3. Services
9.3. By Application
- 9.3.1. Infectious Disease Diagnostics
- 9.3.2. Oncology
- 9.3.3. Genetic & Rare Disease Testing
- 9.3.4. Prenatal & Reproductive Health Testing
- 9.3.5. Cardiovascular Disease Diagnostics
- 9.3.6. Neurological Disorders
- 9.3.7. Others
9.4. By Sample Type
- 9.4.1. Blood
- 9.4.2. Tissue
- 9.4.3. Saliva
- 9.4.4. Urine
- 9.4.5. Others
9.5. By End User
- 9.5.1. Hospitals
- 9.5.2. Clinical Laboratories
- 9.5.3. Pharmaceutical & Biotechnology Companies
- 9.5.4. Others

10. AI-Powered Molecular Diagnostics Market Geographical Analysis (2021-2035)

10.1. North America
10.2. Europe
10.3. Asia-Pacific
10.4. South America
10.5. Middle East & Africa

11. AI-Powered Molecular Diagnostics Market Country Analysis (2021-2035)

11.1. United States
11.2. Canada
11.3. Germany
11.4. United Kingdom
11.5. France
11.6. Italy
11.7. Spain
11.8. Netherlands
11.9. Switzerland
11.10. China
11.11. Japan
11.12. India
11.13. South Korea
11.14. Australia
11.15. Brazil

12. Competitive Landscape

12.1. Market Share Analysis
12.2. Strategic Developments
12.3. Mergers & Acquisitions, Partnerships & Collaborations
12.4. Product Launches

13. Company Profiles

13.1. F. Hoffmann-La Roche Ltd.
- 13.1.1. Company Overview
- 13.1.2. Financials
- 13.1.3. Product Portfolio
- 13.1.4. Recent Developments
13.2. Thermo Fisher Scientific Inc.
13.3. Illumina, Inc.
13.4. QIAGEN N.V.
13.5. Guardant Health
13.6. Tempus AI
13.7. Abbott Laboratories
13.8. Siemens AG
13.9. Agilent Technologies
13.10. Koninklijke Philips N.V.